Who is sponsoring NCT01022255?

NCT01022255 is sponsored by Icon Genetics GmbH.

What condition does NCT01022255 study?

NCT01022255 studies Lymphoma, Follicular.

What drugs are being tested in NCT01022255?

Interventions: Autologous FL vaccine.

What is the status of NCT01022255?

NCT01022255 is currently COMPLETED.

Last reviewed 2014-01-29 · How we verify

Phase I Study of an Autologous Recombinant Idiotypic Vaccine Manufactured by magnICON® Technology for the Treatment of Patients With Relapsed or Transformed Follicular Lymphoma

NCT01022255 Phase 1 COMPLETED

This phase I study will evaluate the safety and tolerability of an autologous idiotype vaccine manufactured by magnICON technology for patients with relapsed follicular lymphoma who are in complete or partial remission following non-antiCD20 containing salvage therapy. Data in terms of idiotype-specific immune responses will also be obtained.

Details

Lead sponsor	Icon Genetics GmbH
Phase	Phase 1
Status	COMPLETED
Enrolment	28
Start date	2010-01
Completion	2013-10

Conditions

Lymphoma, Follicular

Interventions

Autologous FL vaccine

Primary outcomes

Proportion of patients with toxicities as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI/CTCAE) version 3.0 grade >/= 3 to the magnICON generated idiotype (Id) vaccine — One month after sixth vaccination (=7 month after achievement of tumour remission and recovery of normal blood values)

Countries

United States